Remove 2029 Remove Competition Remove Leads Remove Sales
article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029.

article thumbnail

How to Get Qualified B2B Telecom Sales Leads

Spotio

There’s never been a better time to be in telecom sales. billion in the US alone by 2029. In other words, there’s plenty of opportunity—as long as you know how to generate telecom sales leads effectively, of course. Building ICPs for your sales team will keep your reps focused. The result?

Leads 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Guide to the AI Tools for Sales to Optimize Performance in 2023

Quantified

through 2029. Part of that growth comes from using AI tools for professional work, especially sales. According to Gartner, 75% of B2B sales organizations will augment traditional playbooks with AI by 2025 despite the current low adoption rate. Competitive pressure will drive companies to invest in AI tools for sales.

Sales 52
article thumbnail

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. trillion in the Q1 of 2023 to $3.56

article thumbnail

Market cap downturn hits over half of top 20 biopharmaceutical companies in Q1 2023

Pharmaceutical Technology

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. million by 2029. Novo Nordisk reported an 18.2%

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

article thumbnail

Intercept receives orphan drug designation for liver disease combo therapy

Pharmaceutical Technology

This results in bile buildup in the liver and can lead to scarring. According to consensus forecasts from GlobalData’s Pharma Intelligence Centre, Ocaliva is forecasted to have global sales of $1.08 billion in 2029. The condition gradually worsens and can result in liver failure.